A narrative review on antimicrobial therapy in septic shock : updates and controversies
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
PURPOSE OF REVIEW: Antibiotics are an essential treatment for septic shock. This review provides an overview of the key issues in antimicrobial therapy for septic shock. We include a summary of available evidence with an emphasis on data published in the last few years.
RECENT FINDINGS: We examine apparently contradictory data supporting the importance of minimizing time to antimicrobial therapy in sepsis, discuss approaches to choosing appropriate antibiotics, and review the importance and challenges presented by antimicrobial dosing. Lastly, we evaluate the evolving concepts of de-escalation, and optimization of the duration of antimicrobials.
SUMMARY: The topics discussed in this review provide background to key clinical decisions in antimicrobial therapy for septic shock: timing, antibiotic choice, dosage, de-escalation, and duration. Although acknowledging some controversy, antimicrobial therapy in septic shock should be delivered early, be of the adequate spectrum, appropriately and individually dosed, rationalized when possible, and of minimal effective duration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Current opinion in anaesthesiology - 34(2021), 2 vom: 01. Apr., Seite 92-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ling, Lowell [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.03.2021 Date Revised 26.08.2023 published: Print ClinicalTrials.gov: NCT01988428 Citation Status MEDLINE |
|---|
| doi: |
10.1097/ACO.0000000000000954 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320330559 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320330559 | ||
| 003 | DE-627 | ||
| 005 | 20231225173338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/ACO.0000000000000954 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320330559 | ||
| 035 | |a (NLM)33470662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ling, Lowell |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A narrative review on antimicrobial therapy in septic shock |b updates and controversies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2021 | ||
| 500 | |a Date Revised 26.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01988428 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSE OF REVIEW: Antibiotics are an essential treatment for septic shock. This review provides an overview of the key issues in antimicrobial therapy for septic shock. We include a summary of available evidence with an emphasis on data published in the last few years | ||
| 520 | |a RECENT FINDINGS: We examine apparently contradictory data supporting the importance of minimizing time to antimicrobial therapy in sepsis, discuss approaches to choosing appropriate antibiotics, and review the importance and challenges presented by antimicrobial dosing. Lastly, we evaluate the evolving concepts of de-escalation, and optimization of the duration of antimicrobials | ||
| 520 | |a SUMMARY: The topics discussed in this review provide background to key clinical decisions in antimicrobial therapy for septic shock: timing, antibiotic choice, dosage, de-escalation, and duration. Although acknowledging some controversy, antimicrobial therapy in septic shock should be delivered early, be of the adequate spectrum, appropriately and individually dosed, rationalized when possible, and of minimal effective duration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Joynt, Gavin Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Lipman, Jeffrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in anaesthesiology |d 1996 |g 34(2021), 2 vom: 01. Apr., Seite 92-98 |w (DE-627)NLM087824892 |x 1473-6500 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2021 |g number:2 |g day:01 |g month:04 |g pages:92-98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/ACO.0000000000000954 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2021 |e 2 |b 01 |c 04 |h 92-98 | ||